{"id":219695,"date":"2025-08-08T23:13:35","date_gmt":"2025-08-09T04:13:35","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/08\/pelage-pharmaceuticals-announces-positive-phase-2a-clinical-trial-results-for-pp405-in-regenerative-hair-loss-therapy"},"modified":"2025-08-08T23:13:35","modified_gmt":"2025-08-09T04:13:35","slug":"pelage-pharmaceuticals-announces-positive-phase-2a-clinical-trial-results-for-pp405-in-regenerative-hair-loss-therapy","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/08\/pelage-pharmaceuticals-announces-positive-phase-2a-clinical-trial-results-for-pp405-in-regenerative-hair-loss-therapy","title":{"rendered":"Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/pelage-pharmaceuticals-announces-positive-phase-2a-clinical-trial-results-for-pp405-in-regenerative-hair-loss-therapy2.jpg\"><\/a><\/p>\n<p><b><i>Clinical validation of stem cell reactivation approach positions Pelage as leader in regenerative medicine and aging<\/i><\/b><\/p>\n<p>LOS ANGELES\u2014(BUSINESS WIRE)\u2014 #HairLoss \u2014Pelage Pharmaceuticals, a clinical-stage regenerative medicine company, today announced positive results from its Phase 2a clinical trial of PP405 \u2014 a topical therapy for androgenetic alopecia advancing through the FDA clinical development pathway. PP405 is designed to reactivate dormant hair follicle stem cells, offering a potential first-in-class approach for both men and women experiencing hair loss.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Clinical validation of stem cell reactivation approach positions Pelage as leader in regenerative medicine and aging LOS ANGELES\u2014(BUSINESS WIRE)\u2014 #HairLoss \u2014Pelage Pharmaceuticals, a clinical-stage regenerative medicine company, today announced positive results from its Phase 2a clinical trial of PP405 \u2014 a topical therapy for androgenetic alopecia advancing through the FDA clinical development pathway. PP405 is [\u2026]<\/p>\n","protected":false},"author":534,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,43,412,269],"tags":[],"class_list":["post-219695","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-business","category-genetics","category-life-extension"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/219695","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/534"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=219695"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/219695\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=219695"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=219695"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=219695"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}